Novel Drug Candidate EVT0185 Shows Promise for Reversing Liver Fibrosis in Preclinical Studies
核心洞察
McMaster University researchers have demonstrated that EVT0185 (搜索), a novel small-molecule drug candidate, can prevent and reverse liver fibrosis in preclinical disease models, addressing a critical therapeutic gap.
The compound simultaneously targets ACLY (搜索) and ACSS2 (搜索) enzymes to control blood sugar levels, reduce cholesterol, and eliminate fat buildup that causes liver fibrosis through a "carbon release valve" mechanism.
EVT0185 (搜索) represents a potential breakthrough for treating metabolic dysfunction-associated steatohepatitis (MASH), with clinical trials expected to begin by 2027 following completion of preclinical and toxicology studies.
Researchers at McMaster University have published promising preclinical data showing that a novel drug candidate can both prevent and reverse liver fibrosis, potentially offering hope for millions of patients with metabolic liver disease. The compound, EVT0185 (搜索), developed by Espervita Therapeutics (搜索), demonstrated powerful curative and restorative effects in disease models, according to findings published in January 2026 in Cell Metabolism.
The research addresses a critical unmet medical need in treating metabolic dysfunction-associated steatohepatitis (MASH), a condition that most often affects people with obesity or metabolic conditions like type 2 diabetes. Liver fibrosis, characterized by dangerous scar tissue buildup in the liver, represents a late-stage symptom of MASH that can lead to cancer, heart attack, stroke, and ultimately require liver transplantation.
Current Treatment Landscape Reveals Significant Gaps
"Currently, we have no drugs approved in Canada to treat MASH," explained Greg Steinberg, professor in McMaster's Department of Medicine and lead author of the research. "Right now, patients are typically prescribed a Mediterranean diet and some lifestyle and exercise recommendations, but no specific medical interventions have been approved in Canada."
The treatment situation remains challenging even in regions with approved therapies. While two treatments have recently received approval in the US and EU, these agents have only been shown to reduce fibrosis in approximately one-third of patients, according to Steinberg.
The current treatment paradigm can sometimes slow disease progression but generally does not reverse fibrosis-related damage that has already occurred. This limitation makes the potential of EVT0185 (搜索) particularly significant, as early preclinical data suggests the compound can achieve what existing approaches cannot.
Dual-Target Mechanism Shows Multi-System Benefits
EVT0185 (搜索) operates through a unique mechanism that simultaneously targets two critical enzymes: ACLY (搜索) and ACSS2 (搜索), which control fat synthesis and fat burning. This dual targeting triggers what Steinberg describes as a "carbon release valve" in the body, preventing harmful matter from accumulating in the liver and bloodstream by diverting it out through urine.
The research team, working in collaboration with scientists from the United States, France, and Australia, demonstrated that the compound can help control blood sugar levels, reduce cholesterol, and destroy fat buildup that causes liver fibrosis. These multiple effects address what Steinberg identifies as "a huge unmet need for agents that reduce liver fibrosis and also have a positive effect on blood glucose and cholesterol."
From Cancer Treatment to Metabolic Disease
EVT0185 (搜索) was originally characterized as a potential liver cancer treatment, with its promising anti-tumor activity detailed in a paper published in Nature. While the compound continues to hold promise as a cancer therapeutic, this recent discovery expands its potential applications to metabolic liver disease.
"This drug candidate addresses a major therapeutic gap and has the potential to fundamentally change how we treat severe liver disease and, in turn, prevent liver cancer and other complications, including diabetes and heart disease," said Steinberg, who serves as chief scientific officer, shareholder, and co-founder of Espervita Therapeutics (搜索) and co-directs the Centre for Metabolism, Obesity, and Diabetes Research at McMaster.
Clinical Development Timeline
The compound is being evaluated through a research partnership between McMaster University and Espervita Therapeutics (搜索). According to Steinberg, the multi-use compound is on track to enter clinical trials by 2027, pending completion of final preclinical and toxicology studies.
The research was supported by funding from Espervita Therapeutics (搜索), the Canadian Institutes of Health Research, MITACS, and McMaster University, reflecting the collaborative nature of the development effort and institutional commitment to advancing this potential treatment option for patients with severe liver disease.